CLAIMS:

1. The use of an IAP antagonist in the preparation of a medicament for the treatment of an intracellular infection in a subject wherein the IAP antagonist is not LBW242.

2. The use as claimed in claim 1 wherein the IAP is cIAP1 and/or cIAP2.

3. The use as claimed in claim 1 or claim 2 wherein the antagonist is a Smac mimetic.

4. The use as claimed in claim 3, wherein the Smac mimetic comprises one or more of the following characteristics:

    (a) the Smac mimetic is bivalent;

    (b) the Smac mimetic derepresses XIAP-mediated caspase-3 repression;

    (c) the Smac mimetic degrades cIAP-1 not bound to TRAF2 as well as cIAP1 bound to TRAF2;

    (d) the Smac mimetic degrades cIAP-2 bound to TRAF2 but does not degrade cIAP-2 not bound to TRAF2;

    (e) the Smac mimetic weakly degrades cIAP-2 not bound to TRAF2 relative to degradation of cIAP-2 bound to TRAF; and

    (f) the Smac mimetic has the general structure [P1-P2-P3-P4] or [P1-P2-P3-P4]-L-[P1'-P2'-P3'-P4'], wherein P1-P2-P3- and P1'-P2'-P3'- correspond to peptide replacements or peptidomimetics of the N-terminal Ala-Val-Pro-tripeptide of mature Smac and P4 and P4' correspond to amino acid replacements of Phe, Tyr, Ile, or Val, and L is a linking group, or bond, covalently linking [P1-P2-P3-P4] to [P1'-P2'-P3'-P4'].

5. The use as claimed in claim 3 or claim 4 wherein the Smac mimetic is birinapant.

6. The use as claimed in claim 1 wherein the antagonist reduces expression of the IAP gene.

7. The use as claimed in claim 6 wherein the IAP gene is the cIAP1 or cIAP2 gene.

8. The use as claimed in claim 6 or claim 7 wherein the antagonist is siRNA, shRNA or miRNA.

9. The use as claimed in claim 8 wherein the siRNA, shRNA or miRNA is targeted against a sequence selected from the group consisting of NCBI Reference Sequence: NM_001166.4, NCBI Reference Sequence: NM_001256163.1, NCBI Reference Sequence: NM_001256166.1, GenBank: DQ068066.1, NCBI Reference Sequence: NM_001165.4, NCBI Reference Sequence: NM_182962.2, GenBank: BC037420.1, NCBI Reference Sequence: NM_001167.3, NCBI Reference Sequence: NM_001204401.1, NCBI Reference Sequence: NR_037916.1, and NCBI Reference Sequence: NG_007264.1

10. The use as claimed in any one of claims 1 to 9 wherein the infection is caused by a virus selected from the group consisting of Human papillomaviruses, Herpes viruses including herpes simplex 1/2, varicella zoster, EBV, CMV, HHV-6/7, HTLV, Human papillomavirus including JC virus and BK virus, adeno and parvoviruses, HIV, HBV and HCV.

11. The use as claimed in any one of claims 1 to 9 wherein the infection is caused by a bacteria selected from the group consisting of Salmonella spp., Ehrlichia spp., Mycobacteria spp., Spirochetes, Legionella spp., Listeria spp., Rickettsia spp., Chlamydia spp., Mycoplasma spp., Coxiella spp., Yersinia spp., Francisella spp., Brucella spp., Neisseria spp, and Nocardia spp..

12. The use as claimed in any one of claims 1 to 9 wherein the infection is caused by a fungi or yeast selected from the group consisting of Histoplasma spp., Aspergillus spp., Cryptococcus spp., and Pneumocystis jirovecii.

13. The use as claimed in any one of claims 1 to 9 wherein the infection is caused by a protozoa selected from the group consisting of Trypanosomatids including Leishmania spp., Apicomplexans including liver forms of Plasmodium spp., Toxoplasma spp., and Cryptosporidium spp.

14. The use as claimed in claim 10 wherein the virus is HIV and the medicament is to be administered in combination with TNF-α.

15. The use of any of the preceding claims wherein the medicament is to be co-administered with a TNF-α or other TNF receptor agonist.

16. The use of any of the preceding claims wherein the medicament is to be co-administered with TRAIL.

17. The use of any of claims 1 to 10 wherein the medicament is to be co-administered with an anti-viral nucleoside analogue.

18. The use of claim 17 wherein the nucleoside analogue is Entacavir.